Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease-Reference-Cited by-同舟云学术

Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease

Published:2017-06-09 Issue:9 Volume:92 Page:885-891
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Jeryczynski Georg¹,Thiele Jürgen²,Gisslinger Bettina¹,Wölfler Albert³,Schalling Martin¹,Gleiß Andreas⁴,Burgstaller Sonja⁵,Buxhofer-Ausch Veronika⁶,Sliwa Thamer⁷,Schlögl Ernst⁷,Geissler Klaus⁸,Krauth Maria-Theresa¹,Nader Alexander⁹,Vesely Michael¹⁰,Simonitsch-Klupp Ingrid¹¹,Müllauer Leonhard¹¹,Beham-Schmid Christine¹²,Gisslinger Heinz¹^ORCID

Affiliation:

1. Department of Internal Medicine I, Division of Hematology and Hemostaseology; Medical University of Vienna; Vienna Austria

2. Institute of Pathology, University of Cologne; Cologne Germany

3. Division of Hematology, Department of Internal Medicine; Medical University of Graz; Graz Austria

4. Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna; Vienna Austria

5. Department of Internal Medicine IV; Klinikum Wels-Grieskirchen; Wels Austria

6. Department of Internal Medicine I; Elisabethinen Hospital Linz; Linz Austria

7. Department of Internal Medicine 3; Hanusch Hospital; Vienna Austria

8. 5th Medical Department for Hematology and Oncology; Hospital Hietzing; Vienna Austria

9. Institute of Pathology and Microbiology, Hanusch Hospital; Vienna Austria

10. Institute of Pathology, Hospital Hietzing Vienna; Austria

11. Clinical Institute of Pathology, Medical University of Vienna; Vienna Austria

12. Institute of Pathology, Medical University of Graz; Graz Austria

Publisher

Wiley

Subject

Hematology

Reference42 articles.

1. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter;Barosi;Best Pract Res Clin Haematol.,2014

2. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study;Barbui;J Clin Oncol,2011

3. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis;Barbui;Blood.,2012

4. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification;Thiele;Blood.,2011

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis;Annals of Hematology;2024-08-15

2. Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications—A Narrative Review;Current Issues in Molecular Biology;2024-08-02

3. SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-07

4. A lasso and random forest model using flow cytometry data identifies primary myelofibrosis;Cytometry Part B: Clinical Cytometry;2024-04-22

5. Quantitative interpretation of bone marrow biopsies in MPN—What's the point in a molecular age?;British Journal of Haematology;2023-10-19